Abstract: Compositions and methods for treating, detecting, and diagnosing cancer are disclosed.

Abstract: Compositions and methods for treating, detecting, and diagnosing cancer and other diseases and disorders are disclosed.

Abstract: Compositions and methods for treating, detecting, and diagnosing cancer are disclosed.

Abstract: Compounds and compositions for targeting cells expressing norepinephrine transporter, and methods of making and using the same. The compounds comprise MIBG analogs conjugated to active agents for treatment and/or diagnosis of various conditions, including neuroblastoma.

Abstract: Methods of using butyrylcholinesterase targeted, and optionally androgen receptor targeted radiolabeled compounds, e.g., cycloSalingenyl pyrimidine nucleoside monophosphates, for targeted delivery of cytotoxic and/or imaging compounds to cancer cells.

Abstract: Compounds and compositions for targeting cells expressing norepinephrine transporter, and methods of making and using the same. The compounds comprise MIBG analogs conjugated to active agents for treatment and/or diagnosis of various conditions, including neuroblastoma.

Abstract: Method of using androgen receptor and/or butyrylcholinesterase targeted radiolabeled compounds, e.g., cycloSalingenyl pyrimidine nucleoside monophosphates, for the treatment and diagnosis of cancer.

Abstract: Disclosed are certain cycloSalingenyl pyrimidine nucleoside monophosphates comprising positron emitters or gamma-emitting radiohalides, uses thereof for monitoring Alzheimer's disease progression and evaluating response to therapy and process for their preparation.

Abstract: Disclosed are certain cycloSalingenyl pyrimidine nucleoside monophosphates comprising positron emitters or gamma-emitting radiohalides, uses thereof for monitoring Alzheimer's disease progression and evaluating response to therapy and process for their preparation.

Abstract: Radiolabeled conjugates are disclosed which have a component that is effective to target tumor cells, which cells selectively take up and degrade the conjugate, thereby delivering to the tumor cell nucleus a radioisotope capable of being incorporated into the nuclear material, so as to produce a cytotoxic effect and/or to render the cell detectable by radioimaging.

Abstract: 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of the formula I or a pharmaceutically acceptable salt thereof can be used for enhancing the effect of radioimmunotherapy of tumors.

Abstract: Radiolabeled conjugates are disclosed which have a component that is effective to target tumor cells, which cells selectively take up and degrade the conjugate, thereby delivering to the tumor cell nucleus a radioisotope capable of being incorporated into the nuclear material, so as to produce a cytotoxic effect and/or to render the cell detectable by radioimaging.

Abstract: Method of synthesizing 5-radio-halogenated-2'-deoxyuridine from 5-trimethylstannyl-2'-deoxyuridine is described. The method consists of the steps of mixing 5-trimethylstannyl-2'-deoxyuridine with an aqueous solution consisting of a radiohalide and NaOH to form a first mixture, adding H.sub.2 O.sub.2 /CH.sub.3 COOH to the first mixture to form a second mixture, sonicating the second mixture, evaporating the solvent from the second mixture to form a residue, reconstituting the residue, filtering the residue; and then purifying the filtered residue such that at least one of a radiohalogenated nucleoside and nucleotide is obtained. A kit consisting of the components required for the above synthesis is also described.

Abstract: The method of making radioiodinated pyrimidine nucleoside or nucleotide which comprises contacting a water-insoluble halomercuri pyrimidine nucleoside or nucleotide with an aqueous medium containing a dissolved radioactive iodide ion and an oxidizing agent, the molar amounts of said nucleoside or nucleotide and said oxidizing agent being in excess of the molar amount of said iodide, whereby water-soluble radioactive iodinated pyrimidine nucleoside or nucleotide is formed in solution, and separating residual water-insoluble halomercuri pyrimidine nucleoside or nucleotide from said solution.